Prasco Announces Agreement with Shire for Future Exclusive Distribution and Supply of Authorized Generic for PENTASA®

CINCINNATI, Feb. 22, 2011 /PRNewswire/ -- Prasco Laboratories announced today it has signed a distribution and supply agreement with Shire US Manufacturing, Inc. for mesalamine controlled-release capsules.  As part of the agreement, Prasco, LLC is prepared to market the authorized generic version of PENTASA® (mesalamine) Controlled-Release Capsules, at Shire's request, immediately upon any entrance into the United States market of an approved ANDA for any generic mesalamine product which is AB-rated to PENTASA®.  (At the present time, the FDA has not approved any ANDA for PENTASA®.)  The authorized generic will be marketed in the United States in 250 mg and 500 mg strengths under the Prasco label.

"We are excited to have established this new business relationship with Shire," stated Prasco Chief Executive Officer, E. Thomas Arington.  "Patients and pharmacists alike benefit when a company such as Shire commits to maintaining the supply of brand-identical medication through the Prasco Authorized Generic business model," Arington concluded.

PENTASA® is a registered trademark of Ferring A/S Corp.

About Prasco

Prasco is a privately-held pharmaceutical company located in Cincinnati, OH which specializes in Authorized Generics.  Prasco Authorized Generics provide brand pharmaceutical companies with a strategic lifecycle management solution. Prasco sells its product line through the major distribution channels, and operates from a cGMP compliant VAWD certified 160,000 sq. ft. office and distribution center including DEA-approved capabilities for Schedule II-V controlled drug products. For more information, visit www.prasco.com.  

SOURCE Prasco Laboratories